Clinical trials evaluating the efficacy of PARP inhibitors in CML should therefore be stratified by such biomarkers and could potentially be conducted in combination with BCR ABL inhibitors. The gene discussed is PARP1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.